Evidence map›Paper›PMID 37967137›Full record

ArticlePLoS neglected tropical diseases2023

Progress towards elimination of onchocerciasis transmission in Mali: A "pre-stop MDA" survey in 18 transmission zones.

Housseini Dolo, Michel Emmanuel Coulibaly, Moussa Sow, Yaya Ibrahim Coulibaly, Mama Doumbia, Moussa Sangare, Abdoul Sanogo, Benoit Dembele, Boubacar Guindo, Mamadou Coulibaly and 14 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 4 countries.

Housseini DoloNeglected Tropical Diseases Research Unit, Faculty of Medicine and OdontoStomatology, USTTB, Bamako, Mali.
Michel Emmanuel CoulibalyNeglected Tropical Diseases Research Unit, Faculty of Medicine and OdontoStomatology, USTTB, Bamako, Mali.
Moussa SowOnchocerciasis Control Programme, National Health and Public Hygiene, Bamako, Mali.
Yaya Ibrahim CoulibalyNeglected Tropical Diseases Research Unit, Faculty of Medicine and OdontoStomatology, USTTB, Bamako, Mali.
Mama DoumbiaHelen Keller International, Bamako, Mali and Dakar, Senegal.
Moussa SangareNeglected Tropical Diseases Research Unit, Faculty of Medicine and OdontoStomatology, USTTB, Bamako, Mali.
Abdoul SanogoOnchocerciasis Control Programme, National Health and Public Hygiene, Bamako, Mali.
Benoit DembeleHelen Keller International, Bamako, Mali and Dakar, Senegal.
Boubacar GuindoHelen Keller International, Bamako, Mali and Dakar, Senegal.
Mamadou CoulibalySightSavers International, Mali Country Office, Bamako, Mali, and UK Office, Haywards Heath, England, United Kingdom.
Modibo KeitaHelen Keller International, Bamako, Mali and Dakar, Senegal.
Lamine SoumaoroNeglected Tropical Diseases Research Unit, Faculty of Medicine and OdontoStomatology, USTTB, Bamako, Mali.
Dansine DiarraFaculty of History and Geography, University of Social Sciences and Management of Bamako, Bamako, Mali.
Boubacar DickoSightSavers International, Mali Country Office, Bamako, Mali, and UK Office, Haywards Heath, England, United Kingdom.
Louise HamillSightSavers International, Mali Country Office, Bamako, Mali, and UK Office, Haywards Heath, England, United Kingdom.
Seydou DoumbiaFaculty of Medicine and OdontoStomatology, USTTB, Bamako, Mali.
Hamadoun SanghoNeglected Tropical Diseases Research Unit, Faculty of Medicine and OdontoStomatology, USTTB, Bamako, Mali.
Yacouba SangareOnchocerciasis Control Programme, National Health and Public Hygiene, Bamako, Mali.
Yaobi ZhangHelen Keller International, New York, New York State, United States of America.
Jamie TallantThe END Fund, Neglected Tropical Diseases, New York, New York State, United States of America.
Alpha Seydou YaroFaculty of Technical Sciences of Mali, USTTB, Bamako, Mali.
Charles MackenzieThe END Fund, Neglected Tropical Diseases, New York, New York State, United States of America.ORCID 0000-0003-4628-8188
Thomas B NutmanLaboratory of Parasitic Diseases, NIH, Bethesda, Maryland, United States of America.
Daniel BoakyeThe END Fund, Neglected Tropical Diseases, New York, New York State, United States of America.
Université des Sciences, des Techniques et des Technologies de Bamako · MLMinistère de la Santé et de l'Hygiène Publique · MLSightsavers · GBHelen Keller International · USThe Task Force for Global Health · USUniversity of Bamako · MLUniversity of Ghana · GH

Funding

Mali International Center for Excellence in Research: FilariasisZIAAI001063 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NUTMAN, THOMAS · 2009 to 2025
$3.2M
Training Program on Operational and Health Services Research for Malaria in MaliD43TW008652 · FIC · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI SEYDOU DOUMBIA, Alexandre Delamou · 2010 to 2026
$3.1M
FIC NIH HHS D43 TW008652Intramural NIH HHS ZIA AI001063
6 · The paper itself

Abstract

backgroundOnchocerciasis control activities in Mali began in 1975 with vector larviciding carried out by the Onchocerciasis Control Programme (OCP), followed by the distribution of ivermectin from 1998 until the closure of the OCP in 2002. At that time, epidemiological evaluations, using skin snip microscopy and O-150 pool screening PCR in black flies, indicated that the disease had been largely controlled as a public health problem. Ivermectin distribution was nevertheless continued after 2002 in 34 of the 75 health districts in Mali as these were known to still be meso- or hyper-endemic for onchocerciasis. In addition, the onchocerciasis sites known to be hypo-endemic for onchocerciasis benefited from the distribution of ivermectin treatment as part of the mass drug administration (MDA) program for lymphatic filariasis. Various entomological and epidemiological evaluations have now indicated that Mali may have achieved successful interruption of onchocerciasis transmission.

methodsA series of cross-sectional surveys to update vector breeding sites throughout the endemic areas, followed by a pre-stop ivermectin mass drug administration (Pre-stop MDA) survey, were undertaken in 2019-2020. Based on breeding site findings, historical epidemiological assessments, and vector collection site maps, 18 operational transmission zones (OTZ) were delineated within which a total of 104 first line villages were selected for evaluation. Dried blood spots (DBS) samples were collected from 10,400 children (5-9 years old) from these 104 first line villages and processed for the presence of OV16 antibody using a lab-based rapid diagnostic test.

resultsWithin the 544 Simulium damnosum s.l. breeding sites visited in all five endemic onchocerciasis endemic regions of Mali 18.01% (98/544) were seen to be active with the presence of at least one stage of S. damnosum. The overall prevalence of OV16 positive children was 0.45% (47/10,400). However, two hotspots were identified: 2.60% (13/500) seroprevalence in the OTZ number 5 in Kayes Region and 1.40% (7/500) in the OTZ number 1 of Sikasso Region.

conclusionThese data show that onchocerciasis prevalence in the five endemic regions has declined to levels that indicate that Stop-MDA surveys should be now carried out in most of the OTZ except for one in the Kayes Region. This latter site will need additional ivermectin treatment before reevaluation, and an OTZ in the Sikasso Region requires revaluation before possibly reinitiating MDA.

Indexed as

OnchocerciasisSimuliidaeAnimalsChildChild, PreschoolCross-Sectional StudiesHumansIvermectinMaliMass Drug AdministrationSeroepidemiologic StudiesIvermectin

Identifiers

PMID37967137
PMCPMC10686495
OpenAlexW4388693345

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.